The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation.

If you are wondering whether Pfizer's current share price reflects its underlying value, you are not alone. This article will ...

Pfizer Inc. (NYSE:PFE) is included among Dividend Contenders List: Top 20 Stocks. Reuters reported on January 20 that Britain ...

Pfizer remains a Strong Buy, with oncology breakthroughs, a revitalized obesity pipeline, and aggressive cost savings ...

Pfizer's stock has started to turn higher, but it is still down massively; is now the time to jump aboard?

Pfizer's 7% dividend yield ranks among the highest in the healthcare sector, nearly triple the average of the S&P 500. The payout ratio has improved to 89% from over 100% in recent quarters, but ...

Is Back on Investors’ Radar Pfizer (PFE) is attracting fresh attention after a period of mixed share performance, with the ...

Pfizer’s PFE third-quarter revenue fell 6%, as acquisition charges outweighed cost efficiencies and pushed adjusted diluted EPS down 18%. In the battle for Metsera’s obesity pipeline, Pfizer announced ...

Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.

Times of crisis often reveal the character of leaders. "I'm very optimistic," said Bourla, who goes with a "nothing is impossible" mindset. "If there is something about me as a leader ... it is my ...